


Pneumo Update Europe 2016

24-25 June, Prague

Acute Respiratory Failure & Critical Care



Paolo Pelosi, Italy

Agenda

- ❖ **New Clinical Criteria for Sepsis**
- ❖ LUNG SAFE: ARDS in the “real life”
- ❖ Low Tidal Volume in non-ARDS
- ❖ Driving pressure: the “polar star”
- ❖ High-flow oxygen nasal cannula in ARDS
- ❖ The Helmet and risk of intubation in ARDS
- ❖ Tracheostomy: Mortality and QoL

What do **YOU** call sepsis ?

RESPONSE

« Bad infection »

Infection + organ dysfunction

Hypotension


Delirium

Oliguria

DIC

...

SEPSIS – THE CONCEPTS



Sepsis

**A “life-threatening organ dysfunction
due to a dysregulated host response to infection**


| Systemic Inflammatory Response Syndrome (SIRS) Criteria (Range, 0-4 Criteria) | Sequential [Sepsis-related] Organ Failure Assessment (SOFA) (Range, 0-24 Points) | Logistic Organ Dysfunction System (LODS) (Range, 0-22 Points) ^a | Quick Sequential [Sepsis-related] Organ Failure Assessment (qSOFA) (Range, 0-3 Points) |
|---|--|--|--|
| Respiratory rate, breaths per minute | PaO ₂ /FiO ₂ ratio | PaO ₂ /FiO ₂ ratio | Respiratory rate, breaths per minute |
| White blood cell count, 10 ⁹ /L | Glasgow Coma Scale score | Glasgow Coma Scale score | Glasgow Coma Scale score |
| Bands, % | Mean arterial pressure, mm Hg | Systolic blood pressure, mm Hg | Systolic blood pressure, mm Hg |
| Heart rate, beats per minute | Administration of vasopressors with type/dose/rate of infusion | Heart rate, beats per minute | |
| Temperature, °C | Serum creatinine, mg/dL, or urine output, mL/d | Serum creatinine, mg/dL | |
| Arterial carbon dioxide tension, mm Hg | Bilirubin, mg/dL | Bilirubin, mg/dL | |
| | Platelet count, 10 ⁹ /L | Platelet count, 10 ⁹ /L | |
| | | White blood cell count, 10 ⁹ /L | |
| | | Urine output, L/d | |
| | | Serum urea, mmol/L | |
| | | Prothrombin time, % of standard | |

Seymour CW et al. JAMA. 2016;315(8):762-774

Shankar-Ary M JAMA. 2016 Feb 23;315(8):775-87

Singer M et al. JAMA. 2016;315(8):801-810

Sepsis



- ❖ **SEPSIS in ICU settings:**
SOFA score of 2 points or more with infection
- ❖ **SEPSIS in non-ICU settings:**
qSOFA
(consider possibility of Sepsis)

Seymour CW et al. JAMA. 2016;315(8):762-774


Shankar-Ary M JAMA. 2016 Feb 23;315(8):775-87

Singer M et al. JAMA. 2016;315(8):801-810

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP; Clifford S. Deutschman, MD, MS; Christopher Warren Seymour, MD, MSc; Manu Shankar-Hari, MSc, MD, FFICM; Djillali Annane, MD, PhD; Michael Bauer, MD; Rinaldo Bellomo, MD; Gordon R. Bernard, MD; Jean-Daniel Chiche, MD, PhD; Craig M. Coopersmith, MD; Richard S. Hotchkiss, MD; Mitchell M. Levy, MD; John C. Marshall, MD; Greg S. Martin, MD, MSc; Steven M. Opal, MD; Gordon D. Rubenfeld, MD, MS; Tom van der Poll, MD, PhD; Jean-Louis Vincent, MD, PhD; Derek C. Angus, MD, MPH

Box 3. New Terms and Definitions


- 
- Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
 - Organ dysfunction can be identified as an acute change in total SOFA score ≥ 2 points consequent to the infection.
 - The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.
 - A SOFA score ≥ 2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.
 - In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs.

Singer M et al. JAMA. 2016;315(8):801-810

Sepsis: older and newer concepts

Jean-Louis Vincent, Jean-Paul Mira, Massimo Antonelli

Sepsis is a common complication in patients in intensive care units and a frequent reason for intensive care unit admission. Sepsis is a major cause of morbidity and mortality and, without specific antisepsis therapies, management relies on infection control and organ support. For these interventions to be most effective, they must be started early, which highlights the need for all health-care workers to be aware of sepsis so that diagnosis can be made as early as possible. In this Viewpoint, we discuss some of the earlier terms used to characterise and define sepsis, and point out some of their limitations. We then introduce some aspects of new consensus definitions, proposed by an expert panel, which highlight in particular the importance of organ dysfunction. These definitions should help provide a more standardised approach to the identification of patients with suspected sepsis in both clinical practice and clinical research.



Lancet Respir Med 2016 Mar;4(3):237-40

ALARM SIGNAL

quickSOFA (qSOFA)

to identify infected patients with poor outcomes
in prehospital, emergency room and ward settings

- additional tests to evaluate organ function
- prompt intervention
- increased surveillance / transfer to ICU?

- ✓ Tachypnea ($RR \geq 22$ breaths/min)
- ✓ Hypotension (systolic BP ≤ 100 mmHg)
- ✓ Altered Mentation
- ❖ Sat O₂ in air $< 94\%$

THAM = Tachypnea, Hypotension, Altered Mentation

Septic Shock

❖ **Septic shock** can be identified using:

- the clinical criteria of hypotension requiring vasopressor therapy to maintain mean BP 65mmHg or greater
- having a serum lactate level greater than 2 mmol/L after adequate fluid resuscitation

Seymour CW et al. JAMA. 2016;315(8):762-774

Shankar-Ary M JAMA. 2016 Feb 23;315(8):775-87

Singer M et al. JAMA. 2016;315(8):801-810

Agenda

- ❖ New Clinical Criteria for Sepsis
- ❖ **LUNG SAFE: ARDS in the “real life”**
- ❖ Low Tidal Volume in non-ARDS
- ❖ Driving pressure: the “polar star”
- ❖ High-flow oxygen nasal cannula in ARDS
- ❖ The Helmet and risk of intubation in ARDS
- ❖ Tracheostomy: Mortality and QoL

ARDS Incidence

- ❖ **10.4% of all ICU Admissions**
- ❖ **23% of all ventilated ICU patients**
- ❖ **0.45 patients/ICU bed/4 weeks [5.5 patients / ICU bed /year]**
- ❖ **Geographic variation [cases/ICU bed/4 weeks]**
 - Oceania 0.57**
 - Europe 0.48**
 - North America 0.46**
 - Africa 0.32**
 - South America 0.31**
 - Asia 0.27**

Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

ARDS Risk factors

ARDS Risk Factors

| | |
|------------------------------|------------|
| Pneumonia | 1794 (59%) |
| Non pulmonary Sepsis | 484 (16%) |
| Aspiration | 430 (14%) |
| Non cardiogenic shock | 226 (7%) |
| Trauma | 127 (4%) |
| Blood transfusion | 118 (4%) |
| Pulmonary contusion | 97 (3%) |
| Inhalation | 72 (2%) |
| Drug overdose | 56 (2%) |
| Pulmonary vasculitis | 41 (1%) |
| Burn | 9 (0.3%) |
| Drowning | 2 (0.1%) |
| No risk Factor | 252(8%) |

Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800


ARDS Recognition

| Clinician Recognition of ARDS | All | Mild | Moderate | Severe | P value |
|-------------------------------|-----|------|----------|--------|---------|
| On Day 1 (%) | 32% | 26% | 34% | 42% | <0.001 |
| At any time (%) | 60% | 51% | 65% | 78% | <0.001 |

- ❖ The absence of a risk factor for ARDS
- ❖ Lower numbers of nurses and physicians per ICU patient


Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

ARDS PaCO₂




Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

ARDS Tidal Volume



Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

ARDS Plateau Pressure




Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

Use of adjunctive treatments

| | All | Mild | Moderate | Severe | P value ² |
|----------------------------------|----------------|---------------|---------------|---------------|----------------------|
| Neuromuscular Blockade, No. (%), | 516 (21.7) | 34 (6.8) | 208 (18.1) | 274 (37.8) | <0.001 |
| Recruitment maneuvers, No. (%), | 496 (20.9) | 58 (11.7) | 200 (17.4) | 238 (32.7) | <0.001 |
| Prone positioning, No. (%), | 187 (7.9) | 5 (1.0) | 63 (5.5) | 119 (16.3) | <0.001 |
| ECMO, N (%), | 76 (3.2) | 1 (0.2) | 27 (2.4) | 48 (6.6) | <0.001 |
| Inhaled vasodilators, No. (%), | 182 (7.7) | 17 (3.4) | 70 (6.1) | 95 (13.0) | <0.001 |
| HFOV, No. (%), | 28 (1.2) | 3 (0.6) | 14 (1.2) | 11 (1.5) | 0.347 |
| None of the Above, No. (%), | 1431 (60.2) | 397 (79.7) | 750 (65.2) | 284 (39.0) | <0.001 |


Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

ARDS: Adjunctive treatments



Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800


ARDS and Survival




Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

Δ vs Plateau P and Survival

A Driving pressure quintiles and risk of hospital death



B Plateau pressure quintiles and risk of hospital death



Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

LUNG SAFE

- ❖ **ARDS has relatively high Incidence**
Varied from 10.0 - 10.7% of ICU admissions across the different continents
- ❖ **Clinician recognition of ARDS was low**
40% of all cases not being diagnosed.
Clinician recognition rates still <80% in severe ARDS
- ❖ **More than 1/3 of all pts with ARDS received a VT >8 mL/kg PBW**
- ❖ **PEEP 10 cmH₂O or less even in severe ARDS**
- ❖ **Plateau and driving pressure rarely measured**
- ❖ **Adjunctive measures were used relatively infrequently**
 - 22% received NMB
 - 21% received recruitment maneuvers
 - 8% received Prone positioning
 - 3% received ECMO

Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

LUNG SAFE

❖ ARDS continues to have a hospital mortality of 40%

Despite advances in supportive care.

increase in mortality with each increase in ARDS severity category. Overall, 40% of patients with ARDS died in the Hospital

❖ A higher driving pressure is associated with increased risk of death

caution as Pplat was available in a minority of patients.


<80% in severe ARDS

Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800

Agenda


- ❖ New Clinical Criteria for Sepsis
- ❖ LUNG SAFE: ARDS in the “real life”
- ❖ **Low Tidal Volume in non-ARDS**
- ❖ Driving pressure: the “polar star”
- ❖ High-flow oxygen nasal cannula in ARDS
- ❖ The Helmet and risk of intubation in ARDS
- ❖ Tracheostomy: Mortality and QoL

Lung protective ventilation with low V_T and the occurrence of pulmonary complications in non ARDS patients: a systematic review and meta-analysis



Serpa Neto A. et al. Crit Care Med. 2015 Oct;43(10):2155-63

Lung protective ventilation with low V_T and the occurrence of pulmonary complications in non ARDS patients: a systematic review and meta-analysis



Serpa Neto A. et al. Crit Care Med. 2015 Oct;43(10):2155-63

To prevent or cure acute respiratory distress syndrome: that is the question!

Paolo Pelosi^a and Patricia R.M. Rocco

**Protective mechanical ventilation
in ALL patients
JUST DO IT!**

Pelosi P Rocco PR Curr Opin Crit Care 2014 Feb;20(1):1-2.


Pneumonia Update Europe 2016

Agenda

- ❖ New Clinical Criteria for Sepsis
- ❖ LUNG SAFE: ARDS in the “real life”
- ❖ Low Tidal Volume in non-ARDS
- ❖ **Driving pressure: the “polar star”**
- ❖ High-flow oxygen nasal cannula in ARDS
- ❖ The Helmet and risk of intubation in ARDS
- ❖ Tracheostomy: Mortality and QoL

Δ pressure is the “polar star”

$$\Delta P = P_{\text{plat,rs}} - PEEP = V_T / C_{\text{st}} = V_T / E_{\text{ELV}}$$



Samary CS et al. Anesthesiology. 2015 Aug;123(2):423-33

Cressoni M et al. Anesthesiology. 2016 Feb 12. [Epub ahead of print]

Δ pressure is the “polar star”


$$\Delta P = P_{\text{plat,rs}} - \text{PEEP} = V_T / C_{\text{st}} = V_T / E_{\text{ELV}}$$

$$\text{Stress } \sigma = \Delta F / \Delta S \text{ (PL)}$$

$$\text{Energy} = \Delta P^2 \times (2 \times E_{\text{st}})$$

ΔP

$$\text{Strain } \varepsilon = \Delta L / L_0 \text{ (} V_T / E_{\text{ELV}} \text{)}$$



$$\text{Power} = \text{Energy} / \text{Time}$$

Power


$$\Delta P = V_T / C_{\text{st,rs}} = V_T / E_{\text{ELV}}$$

$$\text{Intensity} = \text{Power} / \text{Area}$$

Samary CS et al. Anesthesiology. 2015 Aug;123(2):423-33


Cressoni M et al. Anesthesiology. 2016 Feb 12. [Epub ahead of print]

Driving pressure and survival in the ARDS




Amato MBP, et al. N Engl J Med 2015;372:747-55

Driving pressure and survival in the ARDS



Amato MBP, et al. N Engl J Med 2015;372:747-55

Driving pressure and survival in the ARDS



Bellani G et al. Lung Safe *JAMA* 2016; 315:788–13

Associations between Δ pressure and outcome in patients with severe ARDS: a pooled individual patient data analysis


| | OR (95%CI), <i>p</i> | HR (95%CI), <i>p</i> |
|--------------------------------------|---------------------------|-----------------------------|
| Age, years | 1.04 (1.01 – 1.08), 0.011 | 1.03 (1.01 – 1.05), 0.008 |
| BMI, kg/m ² | 0.94 (0.88 – 1.00), 0.052 | 0.93 (0.88 – 0.97), 0.002 |
| Time between MV-ECMO | | |
| ≤ 24 hours | 1.00 (Reference) | 1.00 (Reference) |
| 24 – 72 hours | 1.49 (0.44 – 4.98), 0.518 | 1.36 (0.57 – 3.26), 0.488 |
| > 72 hours | 2.47 (0.94 – 6.48), 0.066 | 1.04 (0.53 – 2.04), 0.915 |
| Ventilatory Parameters ^a | | |
| FiO ₂ , % | 1.05 (1.01 – 1.08), 0.007 | 1.03 (1.01 – 1.06), 0.008 |
| Driving pressure, cmH ₂ O | 1.14 (1.02 – 1.27), 0.018 | 1.13 (1.07 – 1.21), < 0.001 |
| Laboratory Parameters ^a | | |
| Lactate | 1.02 (1.00 – 1.03), 0.007 | 1.02 (1.01 – 1.02), < 0.001 |

Serpa-Neto A et al. (**Submitted**)

Fan E et al. Intensive Care Med 2016 [Epub Ahead of Print]

Association between Δ pressure and development of PPCs in patients undergoing MV for general anaesthesia: a meta-analysis of individual patient data.


- ❖ 2.679 patients from 15 RCTs
- ❖ Driving P as an independent variable
- ❖ mediation analysis



Serpa-Neto A et al. Lancet Respir Med. 2016 Mar 3. pii: S2213-2600

Association between Δ pressure and development of PPCs in patients undergoing MV for general anaesthesia: a meta-analysis of individual patient data.

- ❖ 2.679 patients from 15 RCTs
- ❖ Driving P as an independent variable
- ❖ mediation analysis





Serpa-Neto A et al. Lancet Respir Med. 2016 Mar 3. pii: S2213-2600

Agenda

- ❖ New Clinical Criteria for Sepsis
- ❖ LUNG SAFE: ARDS in the “real life”
- ❖ Low Tidal Volume in non-ARDS
- ❖ Driving pressure: the “polar star”
- ❖ **High-flow oxygen nasal cannula in ARDS**
- ❖ The Helmet and risk of intubation in ARDS
- ❖ Tracheostomy: Mortality and QoL

High-flow nasal cannula oxygen



Levy SD et al. Lancet 2016; 387: 1867–78


Roca et al. Critical Care (2016) 20:109

Papazian L et al. Intensive Care Med 2016 (Epub Ahead of Print)

High-flow nasal cannula oxygen

> How does it work ?


- Two basics, five benefits :



Papazian L et al. Intensive Care Med 2016 (Epub Ahead of Print)

High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure


- ❖ high-flow oxygen therapy, standard oxygen therapy delivered through a face mask, or noninvasive positive-pressure ventilation



Frat JP et al. N Engl J Med. 2015 Jun 4;372(23):2185-96

High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure


- ❖ high-flow oxygen therapy, standard oxygen therapy delivered through a face mask, or noninvasive positive-pressure ventilation



Frat JP et al. N Engl J Med. 2015 Jun 4;372(23):2185-96

High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure

- ❖ high-flow oxygen therapy, standard oxygen therapy delivered through a face mask, or noninvasive positive-pressure ventilation




No. at Risk

| | | | | | | | |
|-------------------------|-----|-----|----|----|----|----|----|
| High-flow oxygen | 106 | 100 | 97 | 94 | 94 | 93 | 93 |
| Standard oxygen | 94 | 84 | 81 | 77 | 74 | 73 | 72 |
| Noninvasive ventilation | 110 | 93 | 86 | 80 | 79 | 78 | 77 |

Frat JP et al. N Engl J Med. 2015 Jun 4;372(23):2185-96

Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial

- **Low risk for reintubation** was defined as younger than 65 years; Acute Physiology and Chronic Health Evaluation II score less than 12 on day of extubation; body mass index less than 30; adequate secretions management; simple weaning; 0 or 1 comorbidity; and absence of heart failure, moderate-to-severe COPD, airway patency problems, and prolonged MV
- **high-flow or conventional oxygen therapy** for 24 hours after extubation.




| | Oxygen Therapy | |
|---|------------------------|---------------------------|
| | High-Flow (n = 264) | Conventional (n = 263) |
| Exploratory Outcomes, No. (%) | | |
| Respiratory-causes reintubation ^a | 4 (1.5) | 23 (8.7) |
| Immediate postextubation stridor | 2 (0.9) | 9 (4.1) |
| Laryngeal edema requiring reintubation ^a | 0 | 7 (3.1) |

Hernandez G et al. JAMA 2016 Apr 5;315(13):1354-61.

Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure


A Randomized Clinical Trial


❖ early noninvasive ventilation or oxygen therapy alone



| | | | | | |
|-------------------------|-----|-----|-----|-----|-----|
| No. at risk | | | | | |
| Noninvasive ventilation | 191 | 177 | 167 | 153 | 146 |
| Oxygen alone | 183 | 165 | 152 | 140 | 134 |

✓ 2/5 of patients with high-flow oxygen nasal cannulas


| Source | No. of Deaths/Total No. | | Odds Ratio (95% CI) |  |
|---|-------------------------|-------------------------|------------------------|--|
| | Oxygen Alone | Noninvasive Ventilation | | |
| Underlying Conditions | | | | |
| Solid tumors or hematologic malignancies | 43/150 | 41/161 | 0.85 (0.51-1.40) | |
| Immunosuppressive treatment or organ transplant | 7/33 | 5/30 | 0.74 (0.2-2.63) | |
| Oxygen flow at randomization^b | | | | |
| >9 L/min | 26/77 | 24/84 | 0.78 (0.4-1.53) | |
| ≤9 L/min | 24/106 | 22/107 | 0.88 (0.46-1.70) | |
| All patients | 50/183 | 46/191 | 0.84 (0.53-1.34) | |



Lemiale V et al. JAMA. 2015 Oct 27;314(16):1711-9.


High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery A Randomized Clinical Trial

- **high-flow nasal oxygen therapy**: delivered continuously through a nasal cannula (flow, 50 L/min; fraction of inspired oxygen [F_{IO_2}], 50%) (n = 414)
- **BiPAP**: delivered with a full-face mask for at least 4 hours per day (pressure support level, 8 cmH₂O; positive end-expiratory pressure, 4 cmH₂O; F_{IO_2} , 50%)




Stephan F et al. JAMA. 2015 Jun 16;313(23):2331-9

High-flow nasal cannula oxygen versus non-invasive ventilation in patients with acute hypoxaemic respiratory failure undergoing flexible bronchoscopy - a prospective RCT




Simon et al. Critical Care (2014) 18:712.

High-flow nasal cannula oxygen versus non-invasive ventilation in patients with acute hypoxaemic respiratory failure undergoing flexible bronchoscopy - a prospective RCT



Simon et al. Critical Care (2014) 18:712.

High-flow nasal cannula oxygen



Levy SD et al. Lancet 2016; 387: 1867–78

Agenda

- ❖ New Clinical Criteria for Sepsis
- ❖ LUNG SAFE: ARDS in the “real life”
- ❖ Low Tidal Volume in non-ARDS
- ❖ Driving pressure: the “polar star”
- ❖ High-flow oxygen nasal cannula in ARDS
- ❖ **The Helmet and risk of intubation in ARDS**
- ❖ Tracheostomy: Mortality and QoL


The Helmet

- ❖ Equally effective as mask to improve gas exchange and to reduce intubation rate
- ❖ Better tolerated than mask for continuous and prolonged use (days !)
- ❖ Reduces complications related to mask

Antonelli, Conti, Pelosi et al. Crit Care Med 2002; 30: 602-606
Antonelli, Pennisi, Pelosi et al. Anaesthesiology 2004; 100: 16-24

Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Pts With ARDS: A Randomized Clinical Trial

- ❖ patients with ARDS requiring NIV delivered by face mask for at least 8 hours
- ❖ face mask NIV or switch to a helmet for NIV support




Patel BK et al. JAMA. 2016 May 15. doi: 10.1001

Agenda

- ❖ New Clinical Criteria for Sepsis
- ❖ LUNG SAFE: ARDS in the “real life”
- ❖ Low Tidal Volume in non-ARDS
- ❖ Driving pressure: the “polar star”
- ❖ High-flow oxygen nasal cannula in ARDS
- ❖ The Helmet and risk of intubation in ARDS
- ❖ **Tracheostomy: Mortality and QoL**

Hospital and Long-term Outcome After Tracheostomy for Respiratory Failure



decannulated

tracheostomized

**tracheostomized + PSV
or intermittent CMV**

tracheostomized + CMV


Engoren M et al. Chest 2004; 125:220–227

Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis

Pts successfully liberated from the ventilator in the hospital

Event rate (95% CI)

ICUs in acute care hospitals



0.50 (0.46-0.56)

Weaning units in acute care hospitals



0.57 (0.45-0.68)

Post-acute care hospitals




0.49 (0.44-0.53)

0 0.5 1

Damuth E et al. Lancet Respir Med 2015;3: 544–53

Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis


Proportion of patients discharged to home from the hospital



Damuth E et al. Lancet Respir Med 2015;3: 544–53

Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis

Mortality at Hospital discharge



Damuth E et al. Lancet Respir Med 2015;3: 544–53

Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis

Mortality at 1 year

Event rate (95% CI)

ICUs in acute care hospitals

0.58 (0.54-0.61)

Weaning units in acute care hospitals

0.48 (0.36-0.60)

Post-acute care hospitals

0.67 (0.60-0.73)

0 0.5 1

Damuth E et al. Lancet Respir Med 2015;3: 544–53

Long-term survival of critically ill patients treated with prolonged mechanical ventilation: a systematic review and meta-analysis

Mortality at timepoints beyond 1 year

Event rate (95% CI)

ICUs in acute care hospitals

0.69 (0.63-0.74)

Weaning units in acute care hospitals

0.56 (0.45-0.66)

Post-acute care hospitals

0.64 (0.61-0.70)

0 0.5 1


Damuth E et al. Lancet Respir Med 2015;3: 544–53

Mortality and QoL after percutaneous tracheostomy in ICU: An observational study

Mortality 1 yr
88%

Mortality 1 yr
78%

Mortality 1 yr
92%



QoL = 11: mild disability

QoL = 12-15: moderate disability

QoL >15: severe disability

Vargas M et al. (Submitted)

The RECOVER Program: Disability Risk Groups & One Year Outcome after ≥ 7 Days of Mechanical Ventilation


Risk factors for mortality over 1 year after ICU discharge

| | HR | 95% CI | Pr(> z) |
|--|------|------------|----------|
| FIM at day 7 after ICU discharge (per 30 points) | 0.76 | 0.58, 1.00 | 0.0536 |
| Age by decade | 1.27 | 1.07, 1.51 | 0.0056 |
| Female | 0.99 | 0.62, 1.58 | 0.9661 |
| ICU LOS by week | 1.07 | 1.02, 1.13 | 0.0093 |
| Charlson score per point | 1.35 | 1.21, 1.51 | <0.0001 |

Herridge MA et al. Am J Respir Crit Care Med 2016 (Epub Ahead of Print).

Palliative Care for the Seriously Ill


Symptom Prevalence in Advanced Illness



Kelley AS et al. N Engl J Med 2015;373:747-55

One-Year Outcomes in Caregivers of Critically Ill Patients

Caregiver Outcomes during 1^o Year after Patient Discharge from an ICU



- ❖ Center for Epidemiologic Studies Depression (CES-D)
- ❖ Positive Affect Scale of the Positive and Negative Affective Schedule (PANAS)
- ❖ Mental Component Summary (MCS)
- ❖ Physical Component Summary (PCS)

Cameron JI et al. N Engl J Med 2016;374:1831-41

Conclusions

- ❖ New Sepsis and Septic shock definition (NO SIRS):
 - qSOFA for sepsis outside ICU
 - SOFA for sepsis and septic shock in ICU
- ❖ In ARDS, protective MV is rarely applied
- ❖ Protective ventilation in non-ARDS
- ❖ Driving pressure the “polar star”
- ❖ High-flow oxygen NC better than NPPV in ARDS
- ❖ Helmet reduces the risk of intubation in ARDS
- ❖ Tracheostomy is associated with high mortality and poor QoL

List of References

1. Seymour CW et al. JAMA. 2016;315(8):762-774
2. Shankar-Ary M JAMA. 2016 Feb 23;315(8):775-87
3. Singer M et al. JAMA. 2016;315(8):801-810
4. Vincent et al. Lancet Respir Med 2016 Mar;4(3):237-40
5. Bellani G et al. JAMA Feb 23 2016, 315 (8): 788-800
6. Serpa Neto A. et al. Crit Care Med. 2015 Oct;43(10):2155-63
7. Pelosi P Rocco PR Curr Opin Crit Care 2014 Feb;20(1):1-2.
8. Samary CS et al. Anesthesiology. 2015 Aug;123(2):423-33
9. Cressoni M et al. Anesthesiology. 2016 Feb 12. [Epub ahead of print]
10. Amato MBP, et al. N Engl J Med 2015;372:747-55
11. Bellani G et al. Lung Safe JAMA 2016; 315:788–13
12. Fan E et al. Intensive Care Med 2016 [Epub Ahead of Print]
13. Serpa-Neto A et al. Lancet Respir Med. 2016 Mar 3. pii: S2213-2600
14. Levy SD et al. Lancet 2016; 387: 1867–78
15. Roca et al. Critical Care (2016) 20:109
16. Papazian L et al. Intensive Care Med 2016 (Epub Ahead of Print)
17. Frat JP et al. N Engl J Med. 2015 Jun 4;372(23):2185-96
18. Hernandez G et al. JAMA 2016 Apr 5;315(13):1354-61
19. Lemiale V et al. JAMA. 2015 Oct 27;314(16):1711-9

List of References

20. Stephan F et al. JAMA. 2015 Jun 16;313(23):2331-9
21. Simon et al. Critical Care (2014) 18:712
22. Levy SD et al. Lancet 2016; 387: 1867–78
23. Antonelli, Conti, Pelosi et al. Crit Care Med 2002; 30: 602-606
24. Antonelli, Pennisi, Pelosi et al. Anaesthesiology 2004; 100: 16-24
25. Patel BK et al. JAMA. 2016 May 15. doi: 10.1001
26. Engoren M et al. Chest 2004; 125:220–227
27. Damuth E et al. Lancet Respir Med 2015;3: 544–53
28. Vargas M et al. (Submitted)
29. Herridge MA et al. Am J Respir Crit Care Med 2016 (Epub Ahead of Print).
30. Kelley AS et al. N Engl J Med 2015;373:747-55
31. Cameron JI et al. N Engl J Med 2016;374:1831-41